One of the key recommendations from the Transparent Drug System for Patients Act, 2006 is to strengthen the governance of the public drug system including increased transparency and accountability among all stakeholders. As Executive Officer of Ontario Public Drug Programs I am committed to carrying out the spirit and intent of the principles of good drug system governance that are enshrined in the legislation by :

• Striving to meet the needs of Ontarians, as patients, consumers and taxpayers;
• Involving consumers and patients in a meaningful way;
• Operating transparently, to the extent possible, for all persons with an interest in the system, including, without being limited to, patients, health care practitioners, consumers, manufacturers, wholesalers and pharmacies;
• Aiming to consistently achieve value-for-money and ensure the best use of resources at every level of the system;
• Making funding decisions for drugs on the best clinical and economic evidence available, communicating those decisions openly, in as timely a manner as possible.

In this section of the site, you will find a summary of all our communications, news releases, announcements, presentations, report cards, results of public consultations, recommendations from the Committee to Evaluate Drugs and Executive Officer decisions.

Helen Stevenson
Assistant Deputy Minister and Executive Officer
Ontario Public Drug Programs

• Executive Officer Communiqués
• Executive Officer Decisions and CED Recommendations
• Announcements
• Public Consultations
• Regulation Amendments
• Annual Ontario Drug Benefit Program Report Cards
• Presentations
• News Releases